July 30 (Reuters) - Tenaya Therapeutics Inc TNYA.O:
TENAYA RECEIVES POSITIVE SAFETY REVIEWS FROM INDEPENDENT DSMBS TO ADVANCE BOTH TN-201 AND TN-401 GENE THERAPY CLINICAL TRIALS AS DESIGNED
TENAYA THERAPEUTICS INC: PLANS TO REPORT LONGER-TERM FOLLOW-UP DATA FROM COHORT 1 AND INITIAL DATA FROM COHORT 2 IN Q4 OF THIS YEAR